ES2548508T3 - Métodos de tratamiento de enfermedades - Google Patents
Métodos de tratamiento de enfermedades Download PDFInfo
- Publication number
- ES2548508T3 ES2548508T3 ES10779928.0T ES10779928T ES2548508T3 ES 2548508 T3 ES2548508 T3 ES 2548508T3 ES 10779928 T ES10779928 T ES 10779928T ES 2548508 T3 ES2548508 T3 ES 2548508T3
- Authority
- ES
- Spain
- Prior art keywords
- biomarker
- disease
- future
- subject
- fluctuation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/413—Monitoring transplanted tissue or organ, e.g. for possible rejection reactions after a transplant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
- A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Software Systems (AREA)
- Primary Health Care (AREA)
- Evolutionary Computation (AREA)
- Bioethics (AREA)
Abstract
Un método implementado por ordenador para el análisis de un biomarcador que fluctúa en un sujeto con una enfermedad para determinar un tiempo preferido en el futuro para administrar una terapia para el tratamiento de dicha enfermedad, comprendiendo el método: a) la estimación de una periodicidad de la fluctuación del biomarcador con base en las mediciones del biomarcador en muestras del sujeto mediante la obtención de una curva de mejor ajuste para las mediciones de acuerdo con un modelo de la fluctuación del biomarcador, en donde el modelo es una técnica de regresión periódica; y b) determinar a partir de la periodicidad estimada de la fluctuación un tiempo preferido en el futuro para administrar una terapia para tratar la enfermedad en el sujeto mediante la proyección de la curva obtenida de mejor ajuste en el futuro.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18150809P | 2009-05-27 | 2009-05-27 | |
US181508P | 2009-05-27 | ||
PCT/AU2010/000649 WO2010135781A1 (en) | 2009-05-27 | 2010-05-27 | Methods of treating diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2548508T3 true ES2548508T3 (es) | 2015-10-19 |
Family
ID=43222057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10779928.0T Active ES2548508T3 (es) | 2009-05-27 | 2010-05-27 | Métodos de tratamiento de enfermedades |
Country Status (11)
Country | Link |
---|---|
US (4) | US9122778B2 (es) |
EP (2) | EP2435825B8 (es) |
AU (1) | AU2010251880B2 (es) |
CA (1) | CA2763373C (es) |
DK (1) | DK2435825T3 (es) |
ES (1) | ES2548508T3 (es) |
HK (2) | HK1167017A1 (es) |
HU (1) | HUE026456T2 (es) |
PL (1) | PL2435825T3 (es) |
PT (1) | PT2435825E (es) |
WO (1) | WO2010135781A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030228320A1 (en) * | 2000-08-18 | 2003-12-11 | Ashdown Martin Leonard | Retroviral immunotherapy |
AUPS054702A0 (en) * | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
BRPI0415533A (pt) * | 2003-10-24 | 2006-12-26 | Immunaid Pty Ltd | método de terapia |
US20080248022A1 (en) * | 2004-09-08 | 2008-10-09 | Immunaid Pty Ltd | Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases |
ES2548508T3 (es) | 2009-05-27 | 2015-10-19 | Biotempus Limited | Métodos de tratamiento de enfermedades |
EP2488553B1 (en) | 2009-10-12 | 2015-06-17 | Pfizer Inc. | Cancer treatment |
US20150177250A1 (en) * | 2012-06-18 | 2015-06-25 | Mayo Foundation For Medical Education And Research | Determination of efficient time(s) for chemotherapy delivery |
US11207241B2 (en) | 2013-03-15 | 2021-12-28 | Phd Preventative Health Care And Diagnostics, Inc. | Prefilled medication device, method of making and using the same |
CN107205645A (zh) * | 2014-12-05 | 2017-09-26 | 生命循环科技私人有限公司 | 改善生理反应的方法和系统 |
US11164596B2 (en) | 2016-02-25 | 2021-11-02 | Samsung Electronics Co., Ltd. | Sensor assisted evaluation of health and rehabilitation |
US10172517B2 (en) | 2016-02-25 | 2019-01-08 | Samsung Electronics Co., Ltd | Image-analysis for assessing heart failure |
US10420514B2 (en) | 2016-02-25 | 2019-09-24 | Samsung Electronics Co., Ltd. | Detection of chronotropic incompetence |
US10362998B2 (en) | 2016-02-25 | 2019-07-30 | Samsung Electronics Co., Ltd. | Sensor-based detection of changes in health and ventilation threshold |
EP3542859A1 (en) | 2018-03-20 | 2019-09-25 | Koninklijke Philips N.V. | Determining a medical imaging schedule |
CN110764975B (zh) * | 2018-07-27 | 2021-10-22 | 华为技术有限公司 | 设备性能的预警方法、装置及监控设备 |
CN110083951B (zh) * | 2019-04-30 | 2023-06-02 | 贵州电网有限责任公司 | 一种基于变压器相关运行数据的固体绝缘寿命预测方法 |
CN112652402B (zh) * | 2020-12-11 | 2021-10-15 | 华中科技大学 | 一种基于磁纳米粒子谐波响应的病毒检测方法及系统 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
US5308626A (en) | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
US5141867A (en) | 1987-02-02 | 1992-08-25 | E. I. Du Pont De Nemours And Company | Nucleotide sequence encoding a human immunodeficiency virus antigen |
US5057423A (en) | 1987-12-18 | 1991-10-15 | University Of Pittsburgh | Method for the preparation of pure LAK-active lymphocytes |
DE3812605A1 (de) | 1988-04-15 | 1990-06-07 | Leskovar Peter Dipl Ing Dr Hab | Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes |
US20020094542A1 (en) | 1988-04-15 | 2002-07-18 | Peter Leskovar | Drugs and methods for treating cancer |
AU622926B2 (en) | 1988-09-09 | 1992-04-30 | Nippon Kayaku Kabushiki Kaisha | Pyrimidine or purine cyclobutane derivatives |
AU641375B2 (en) | 1988-12-20 | 1993-09-23 | Clarity Technologies Incorporated | Synthetic HIV-like peptides, their compositions and uses |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5925643A (en) | 1990-12-05 | 1999-07-20 | Emory University | Enantiomerically pure β-D-dioxolane-nucleosides |
IL102092A (en) | 1991-06-11 | 1996-11-14 | Microgenesys Inc | Use of recombinant VIH protein wrapped in VIH abduction drug and a pharmaceutical preparation containing the accumulated protein |
DE4120296A1 (de) | 1991-06-28 | 1992-03-19 | Regina Tilgner | Rein pflanzliches kombinationspraeparat - gegen aids |
US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
WO1994007921A1 (en) | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
US5358852A (en) | 1992-12-21 | 1994-10-25 | Eastman Kodak Company | Use of calcium in immunoassay for measurement of C-reactive protein |
JP2877673B2 (ja) | 1993-09-24 | 1999-03-31 | 富士通株式会社 | 時系列データ周期性検出装置 |
ATE475668T1 (de) | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | Immunisierung durch impfung von dns transkriptionseinheit |
MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
IL117574A0 (en) | 1995-04-03 | 1996-07-23 | Bristol Myers Squibb Co | Processes for the preparation of cyclobutanone derivatives |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
US5939400A (en) | 1996-02-26 | 1999-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for induction of suppressive T cell response |
US6077665A (en) | 1996-05-07 | 2000-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Rapid assay for infection in neonates |
AU3210997A (en) | 1996-05-24 | 1997-12-09 | University Of Maryland At Baltimore | Dna vaccines for eliciting a mucosal immune response |
US20040203024A1 (en) | 1996-06-06 | 2004-10-14 | Baker Brenda F. | Modified oligonucleotides for use in RNA interference |
ZA975889B (en) | 1996-07-08 | 1998-02-23 | Genentech Inc | HIV envelope polypeptides and vaccine. |
US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
US6107020A (en) | 1996-09-20 | 2000-08-22 | Roger Williams Hospital | Model for protective and pathogenic roles of HIV-1 env-directed antibody dependent cellular cytotoxicity interaction with viral load, and uses thereof |
US7030152B1 (en) | 1997-04-02 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
JPH11271304A (ja) | 1998-03-24 | 1999-10-08 | Jcr Pharmaceuticals Co Ltd | Hiv感染の診断方法 |
JP2003528564A (ja) | 1998-06-06 | 2003-09-30 | ジェノスティック ファーマ リミテッド | 遺伝的プロファイリングに使用するプローブ |
WO2001008702A2 (en) | 1999-07-28 | 2001-02-08 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Immunotherapy in hiv infected persons using vaccines after multi-drug treatment |
US6980958B1 (en) | 2000-01-11 | 2005-12-27 | Zycare, Inc. | Apparatus and methods for monitoring and modifying anticoagulation therapy of remotely located patients |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
AUPS065002A0 (en) | 2002-02-20 | 2002-03-14 | Immunaid Pty Ltd | Strategy for retroviral immunotherapy |
US20030228320A1 (en) | 2000-08-18 | 2003-12-11 | Ashdown Martin Leonard | Retroviral immunotherapy |
AUPQ948800A0 (en) | 2000-08-18 | 2000-09-07 | Immunaid Pty Ltd | A vaccine strategy |
WO2002045735A2 (en) | 2000-12-08 | 2002-06-13 | University Technologies International, Inc. | Nrp-derived peptides useful for treating insulin-dependent diabetes mellitus |
AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
US20060134713A1 (en) | 2002-03-21 | 2006-06-22 | Lifescan, Inc. | Biosensor apparatus and methods of use |
CA2504926C (en) | 2002-11-01 | 2014-01-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of hif-1 alpha |
DE60329416D1 (de) | 2002-11-04 | 2009-11-05 | Univ Massachusetts | Allelspezifische rna-interferenz |
US7867475B2 (en) | 2003-01-31 | 2011-01-11 | Universidad Autonoma De Madrid | Immune regulation based on the depletion of CD69+ cells |
AU2003279088A1 (en) | 2003-09-10 | 2005-04-27 | Chiron Corporation | Prion chimeras and uses thereof |
BRPI0415533A (pt) | 2003-10-24 | 2006-12-26 | Immunaid Pty Ltd | método de terapia |
US20050186207A1 (en) | 2004-01-08 | 2005-08-25 | The Regents Of The University Of California | Regulatory T cells suppress autoimmunity |
WO2005072777A2 (en) | 2004-01-28 | 2005-08-11 | Curix Aps | Conjugates of amyloid proteins as vaccines for amyloid-related diseases |
US20080248022A1 (en) | 2004-09-08 | 2008-10-09 | Immunaid Pty Ltd | Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases |
WO2006037485A2 (en) | 2004-09-30 | 2006-04-13 | Bayer Healthcare Ag | Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy |
FR2877227B1 (fr) | 2004-11-03 | 2008-01-04 | Braun Medical Soc Par Actions | Systeme medical d'injection a optimisation de therapie |
RU2007124523A (ru) | 2004-12-30 | 2009-02-10 | ПРОВЕНТИС, Инк., (US) | Способы, системы и компьютерные программные продукты для разработки и использования прогнозных моделей для прогнозирования большинства медицинских случаев, оценки стратегий вмешательства и для одновременной оценки нерегулярности биологических маркеров |
EP1872815A4 (en) | 2005-03-07 | 2011-04-27 | Univ Juntendo | SUBCUTANEOUS INSULIN THERAPY WITH PERFUSION CONTINUES |
US20090061422A1 (en) | 2005-04-19 | 2009-03-05 | Linke Steven P | Diagnostic markers of breast cancer treatment and progression and methods of use thereof |
US20070172844A1 (en) | 2005-09-28 | 2007-07-26 | University Of South Florida | Individualized cancer treatments |
GB2436616A (en) | 2006-03-29 | 2007-10-03 | Inverness Medical Switzerland | Assay device and method |
WO2008095136A2 (en) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Methods for detection of biological substances |
US20090105167A1 (en) | 2007-10-19 | 2009-04-23 | Duke University | Predicting responsiveness to cancer therapeutics |
JP5945096B2 (ja) | 2008-07-04 | 2016-07-05 | 小野薬品工業株式会社 | 抗ヒトpd−1抗体の癌に対する治療効果を最適化するための判定マーカーの使用 |
ES2548508T3 (es) | 2009-05-27 | 2015-10-19 | Biotempus Limited | Métodos de tratamiento de enfermedades |
WO2011075225A1 (en) | 2009-12-17 | 2011-06-23 | Mayo Foundation For Medical Education And Research | Determination of favorable time(s) for chemotherapy delivery |
US20150177250A1 (en) | 2012-06-18 | 2015-06-25 | Mayo Foundation For Medical Education And Research | Determination of efficient time(s) for chemotherapy delivery |
-
2010
- 2010-05-27 ES ES10779928.0T patent/ES2548508T3/es active Active
- 2010-05-27 AU AU2010251880A patent/AU2010251880B2/en not_active Ceased
- 2010-05-27 DK DK10779928.0T patent/DK2435825T3/en active
- 2010-05-27 PT PT107799280T patent/PT2435825E/pt unknown
- 2010-05-27 EP EP10779928.0A patent/EP2435825B8/en active Active
- 2010-05-27 PL PL10779928T patent/PL2435825T3/pl unknown
- 2010-05-27 CA CA2763373A patent/CA2763373C/en active Active
- 2010-05-27 EP EP15170346.9A patent/EP2982978A1/en not_active Withdrawn
- 2010-05-27 HU HUE10779928A patent/HUE026456T2/en unknown
- 2010-05-27 US US13/322,357 patent/US9122778B2/en active Active
- 2010-05-27 WO PCT/AU2010/000649 patent/WO2010135781A1/en active Application Filing
-
2012
- 2012-08-06 HK HK12107718.2A patent/HK1167017A1/xx not_active IP Right Cessation
-
2013
- 2013-01-10 US US13/738,580 patent/US9268908B2/en active Active
- 2013-03-21 US US13/848,128 patent/US9239904B2/en active Active
-
2016
- 2016-01-12 US US14/993,845 patent/US10714208B2/en active Active
- 2016-05-19 HK HK16105744.0A patent/HK1217763A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2435825B8 (en) | 2015-09-02 |
CA2763373C (en) | 2018-01-09 |
US20160125125A1 (en) | 2016-05-05 |
HUE026456T2 (en) | 2016-05-30 |
PL2435825T3 (pl) | 2015-12-31 |
AU2010251880A1 (en) | 2011-12-22 |
EP2982978A1 (en) | 2016-02-10 |
DK2435825T3 (en) | 2015-10-19 |
EP2435825A1 (en) | 2012-04-04 |
US9239904B2 (en) | 2016-01-19 |
WO2010135781A1 (en) | 2010-12-02 |
US20130218475A1 (en) | 2013-08-22 |
PT2435825E (pt) | 2015-11-02 |
HK1167017A1 (en) | 2012-11-16 |
US20130151165A1 (en) | 2013-06-13 |
US9268908B2 (en) | 2016-02-23 |
US10714208B2 (en) | 2020-07-14 |
HK1217763A1 (zh) | 2017-01-20 |
CA2763373A1 (en) | 2010-12-02 |
US20120220640A1 (en) | 2012-08-30 |
US9122778B2 (en) | 2015-09-01 |
EP2435825B1 (en) | 2015-07-15 |
AU2010251880B2 (en) | 2015-07-30 |
EP2435825A4 (en) | 2012-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2548508T3 (es) | Métodos de tratamiento de enfermedades | |
CL2020002805A1 (es) | Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526) | |
EA201591754A1 (ru) | Человеческие антитела к na1.7 | |
EA201591417A1 (ru) | Новый способ диагностики депрессии и мониторинга эффективности терапии | |
CR20160252A (es) | Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa | |
MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
BR112015017767A2 (pt) | sistema para detectar estágios do sono de um indivíduo, método para detectar estágios do sono de um indivíduo, e, sistema configurado para detectar estágios do sono de um indivíduo | |
BR112015018213A2 (pt) | método para determinar a síndrome da angústia respiratória aguda (ards) relacionada aos biomarcadores, um método para monitorar o desenvolvimento e o tratamento da ards em um paciente | |
EA201591582A1 (ru) | Анализ транскриптома материнской плазмы с применением массивного параллельного секвенирования рнк | |
BR112015013349A2 (pt) | trieptanoína para o tratamento de deficiência de transportador de glicose 1 | |
UY29777A1 (es) | Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión. | |
AR088813A1 (es) | Metodo para cuantificar el tratamiento de cancer | |
EA201891664A1 (ru) | Составы/композиции, содержащие ингибитор btk | |
NZ729773A (en) | Biomarkers for disease progression in melanoma | |
CY1118400T1 (el) | Αναστολεις υποδοχεα nmda για την θεραπεια δρεπανοκυτταρικης αναιμιας | |
AR092423A1 (es) | Metodo de diagnostico y tratamiento del cancer dirigido a las moleculas expresadas en celulas madre cancerosas | |
EA201500765A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
DOP2012000316A (es) | Metodo para diagnosticar una respuesta al tratamiento en sujetos con esclerosis multiple | |
AR078101A1 (es) | Metodos para diagnosticar la diabetes y determinar la eficacia de tratamientos | |
BR112015029599A2 (pt) | tinturas ácidas, processo para a produção das mesmas e seu uso | |
ES2528394B1 (es) | Procedimiento de hidrólisis de biomasa lignocelulósica | |
RU2012144141A (ru) | Способ оценки вероятности возникновенения переломов при остеопорозе у женщин | |
RU2011117771A (ru) | Способ постановки диагноза у больного в критическом состоянии | |
UA126152U (uk) | Цис-2-(трифлуорометил)циклогексилметиламін | |
RU2011127131A (ru) | Способ прогнозирования выраженности митохондриальной дисфункции у пациентов с острым инфарктом миокарда |